PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE:

Amended and Restated Assignment Agreement of 50% interest to Enzon

Pharmaceuticals, Inc. effective July 26, 2006

CONVEYING PARTY DATA

Name	Execution Date
Santaris Pharma A/S	04/20/2009

RECEIVING PARTY DATA

Name:	Enzon Pharmaceuticals, Inc.
Street Address:	20 Kingsbridge Road
City:	Piscataway
State/Country:	NEW JERSEY
Postal Code:	08854

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	12249676	

CORRESPONDENCE DATA

Fax Number: (212)698-3599

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 2126983500

Email: donna.tirella@dechert.com

Correspondent Name: Dechert LLP
Address Line 1: P.O. Box 390460

Address Line 4: Mountain View, CALIFORNIA 94039-0460

ATTORNEY DOCKET NUMBER: 366929-024D1 (101709)

NAME OF SUBMITTER: Donna M. Tirella

Total Attachments: 2

source=024US-24D1-Assignment#page1.tif source=024US-24D1-Assignment#page2.tif

PATENT REEL: 022650 FRAME: 0730 \$40.00 1224

CH \$40 00

500854112 REEL: 0

AMENDED AND RESTATED ASSIGNMENT AGREEMENT

WHEREAS, Santaris Pharma A/S, a Danish corporation having an office and a place of business at Kogle Allé 6, DK-2970, Hørsholm, Denmark ("Santaris") and Enzon Pharmaceuticals, Inc. f/k/a Enzon Inc., a Delaware Corporation having a principal place of business at 20 Kingsbridge Road, Piscataway, NJ 08854, United States ("Enzon") entered into a License and Collaboration Agreement dated July 26, 2006 (the "Collaboration Agreement");

WHEREAS, pursuant to Article 8 of the Collaboration Agreement, effective as of July 26, 2006, Santaris assigned to Enzon an undivided one-half (50%) right, title and interest in the Assigned Patents (defined below), without the need for any further action by any party; and

WHEREAS, the parties executed and recorded certain assignment agreements relating to the Assigned Patents dated respectively as of March 22, 2007 (the "March 2007 Agreement") and August 21, 2007 (the "August 2007 Agreement"), which agreements contain certain errors, and the parties desire to revoke and nullify such agreements.

NOW THEREFORE, be it known that for and in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

- 1. Each of the March 2007 Agreement and the August 2007 Agreement is hereby revoked and null and void *nunc pro tunc*. This Amended and Restated Assignment Agreement is intended to amend and supersede each of the March 2007 Agreement and the August 2007 Agreement in its entirety.
- 2. Santaris and Enzon hereby confirm and agree that, effective as of July 26, 2006, Santaris assigned to Enzon, its successors and assigns, and Enzon accepted on behalf of itself and its successors and assigns, an undivided one-half (50%) right, title and interest in and to the patent application entitled "LNA Oligonucleotides and the Treatment of Cancer", said application being identified as U.S. patent application serial number 11/272,124 filed on November 9, 2005 together with any other patents issuing in the United States from the foregoing, including without limitation any division, substitution, continuation, continuation-in-part, reissue, reexamination or extension (collectively, the "Assigned Patents").
- 3. Santaris has agreed to execute upon request of Enzon, and at Enzon's expense, such additional documents, if any, as are necessary and proper to secure patent protection on the Assigned Patents in the United States, and to otherwise give full effect to and perfect the rights of Enzon under the Collaboration Agreement.

PATENT REEL: 022650 FRAME: 0731 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Assignment Agreement on the date indicated hereinafter.

Santaris Pharma A/S					
Ву:		Maja Bojko	20 April 2009		
	Name:	Director IP	Date		
	Title:	SANTARIS PHARMA	·		
Witne	ssed by:	James section	20 APR 2009		
Name	•	TAMMY BOGESTRAND	Date		
Enzon Pharmaceuticals, Inc.					
Bx: May 5, 3009					
Name: Margaret Albanese Date					
Title: \Director, Intell. Property					
	ssed by:	CarolSmith	May 5, 2009.		
Name:		CAROL SMITH	Date //		

15024351.1.BUSINESS

PATENT REEL: 022650 FRAME: 0732

RECORDED: 05/07/2009